Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Quoin Pharmaceuticals Logo
Quoin Pharmaceuticals Growth Score
60
CB Rank
72610
Heat Score
68
Quoin Pharmaceuticals is into developing products which address major unmet medical needs.
Founded
obfuscation
PublicPost-IPO Equity Ashburn, Virginia, United States1-10 quoinpharma.com/
Biotechnology
Medical
Pharmaceutical
Overview

Quoin Pharmaceuticals
Total Funding
obfuscation
Growth Score
60
Heat Score
68

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score60
-2 pts
in past quarter
Heat Score 68
11 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Quoin Pharmaceuticals

CB Rank
72610
Quoin Pharmaceuticals is into developing products which address major unmet medical needs.
Founded
obfuscation
PublicPost-IPO Equity Ashburn, Virginia, United States1-10 quoinpharma.com/
Biotechnology
Medical
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

  • Photo of Michael Myers
    Michael Myers: Co-Founder and Chief Executive Officer
    Past Role: Innocoll Holdings, CEO
  • Photo of Sally Lawlor
    Sally Lawlor: Chief Financial Officer
    Past Role: Sebela Pharmaceuticals, Senior Director of Group Tax

Details

Legal Name Quoin Pharmaceuticals, Inc.
Also Known As Cellect Biotechnology
Operating Status Active
Stock Symbol  NASDAQ:QNRX
Company Type For Profit
Founders  Denise Carter, Michael Myers
About the Company
Quoin Pharmaceuticals is into developing products which address major unmet medical needs including the opioid epidemic and the military veteran suicide rate and chronic rare skin diseases such as Netherton syndrome and Dystrophic Epidermolysis Bullosa (DEB).
Phone Number 972 58-448-8821
Contact Email INFO@quoinpharma.com
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
Quoin Pharmaceuticals is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

QRX003
A once-daily topical lotion containing a broad-spectrum serine protease inhibitor formulated with Invisicare® technology, developed to treat Netherton Syndrome and other rare skin diseases.

Research & Development

Quoin Pharmaceuticals is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Quoin Pharmaceuticals Logo
Post-IPO Equity - Quoin Pharmaceuticals
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Quoin Pharmaceuticals Logo
Post-IPO Equity - Quoin Pharmaceuticals
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Quoin Pharmaceuticals Logo
Post-IPO Equity - Quoin Pharmaceuticals
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Quoin Pharmaceuticals Logo
Post-IPO Equity - Quoin Pharmaceuticals
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Quoin Pharmaceuticals Logo
Post-IPO Equity - Quoin Pharmaceuticals
7
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Quoin Pharmaceuticals Logo
Post-IPO Equity - Quoin Pharmaceuticals
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Quoin Pharmaceuticals Logo
Post-IPO Equity - Quoin Pharmaceuticals
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Quoin Pharmaceuticals Logo
Post-IPO Equity - Quoin Pharmaceuticals
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Quoin Pharmaceuticals Logo
Post-IPO Equity - Quoin Pharmaceuticals
7
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Quoin Pharmaceuticals Logo
Post-IPO Equity - Quoin Pharmaceuticals
7
obfuscation
— Post-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 2 Board Members and Advisors 1 Contacts 2

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

2,417
69.85%
 in past month

IT Spend

$699.1KThis year, Quoin Pharmaceuticals is projected to spend $699.1K on IT, according to Aberdeen.

Active Website Tech Count

18Quoin Pharmaceuticals is actively using 18 technologies for its website, according to BuiltWith. These include CommonCrawl Top 50m, HSTS, and  IPv6.

Total IP

7The intellectual property of Quoin Pharmaceuticals includes 2 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Quoin Pharmaceuticals has registered 5 trademarks with the most popular class being 'Scientific and technological services', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Quoin Pharmaceuticals's headquarters? Quoin Pharmaceuticals is located in Ashburn, Virginia, United States.Who invested in Quoin Pharmaceuticals? Quoin Pharmaceuticals has 7 investors including AIGH Capital Management and  StonePine Capital Partners.When was the last funding round for Quoin Pharmaceuticals? Quoin Pharmaceuticals closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Quoin Pharmaceuticals's competitors? Alternatives and possible competitors to Quoin Pharmaceuticals may include Sagimet Biosciences, Concerto Biosciences, and  Palisade Bio.How much funding has Quoin Pharmaceuticals raised to date? Quoin Pharmaceuticals has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5e30c08 1)
|